首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Combination of rapamycin and IL-2 do not affect antigen presentation ability of rat B cell and could promote Tregs proliferation and inhibitory activity
Authors:Chuntao Zhang  Jun Lu  Li Feng  Shengfu Li  Youping Li
Institution:a Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan Province, People’s Republic of China
b Hepato-bilio-pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan Province, People’s Republic of China
c Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, People’s Republic of China
Abstract:Rapamycin (RPM), a powerful agent used clinically in transplant recipients, induces CD4+CD25+ regulatory T cells (Tregs) which play an important role in induction of immune tolerance. However, long-term use of RPM has negative side effects. In this report, we found that combination with the low dose RPM and high dose IL-2 did not affect antigen presentation of rat B cells to Tregs, and could efficiently promote Tregs proliferation and enhance their inhibitory activities in vitro. In addition, the combination of low dose RPM and high dose IL-2 enhanced mRNA expression of Foxp3, TGF-β1 and Pim-2 in Tregs but not in CD4+CD25 T effector cells (Teffs). The Tregs inhibitory activity is positively associated with mRNA expressions of TGF-β1 and Pim-2 while unrelated to the Foxp3 mRNA expression. Our present study offers one approach to expand functional Tregs in vitro, which maybe used for clinical immune tolerance induction.
Keywords:Tregs  CD4+CD25+ regulatory T cells  RPM  rapamycin  Teffs  CD4+CD25&minus   T effector cells  DC  dendritic cells  TGF-β1  transforming growth factor-β1  CAMK  calcium/calmodulin-regulated kinase  Pim  proviral integration of MMLV  LEW  lewis rats  BN  brown Norway rats
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号